MEDPAGE TODAY: A cellular immuno-therapy appears to prolong survival among men with metastatic, castration-resistant prostate cancer, researchers report. READ MORE>
Archive for the ‘Immunotherapy’ Category
Prostate cancer drug market will double in value in next decade
Posted in Immunotherapy, New prostate drugs, tagged catheter, emerging prostate drugs, PR NEWSWIRE, prostablog, prostate, prostate blog, PROSTATE CANCER, prostate cancer drug market, prostate cancer treatments on July 24, 2010| Leave a Comment »
PR NEWSWIRE: The launch and uptake of nine emerging therapies will drive the prostate cancer drug market to more than double, from nearly $4 billion in 2009 to $8.4 billion in 2019 in the US, France, Germany, Italy, Spain, the UK and Japan. READ MORE>
Problems delivering genes to target cells must be solved for immunotherapy to work
Posted in Immunotherapy, PROSTATE CANCER, tagged cancer research, catheter, gene medicine, immunotherapy, prostablog, prostate, prostate blog, PROSTATE CANCER, prostate cancer treatments, prostate treatment debate, target cells, tissue safety on May 29, 2010| Leave a Comment »
URO TODAY: Technological difficulties must be addressed before an efficient and safe gene medicine using immunotherapy is achieved (primarily by developing a means of delivering genes to the target cells or tissue safely and efficiently). READ MORE>
Prostate cancer cells in mice turn anti-tumour T-cells into cells that suppress immune system
Posted in Immunotherapy, PROSTATE CANCER, PROSTATE RESEARCH, tagged anti-tumour T-cells, cancer research, immune cells, immune responses, immune system, immune-based therapies, prostablog, prostate, prostate blog, PROSTATE CANCER, prostate treatment, suppressive functions, tumor-specific CD8+ T cells, URO TODAY, US NATIONAL CANCER INSTITUTE on October 9, 2009| Leave a Comment »
URO TODAY: Researchers have discovered that prostate tumours in mice can cause immune cells known as CD8+ T cells to change to cells that suppress immune responses. READ MORE>
This finding, by researchers at the US National Cancer Institute, has important implications for the design of immune-based therapies for cancer.
Future work by this team will focus on defining the mechanisms by which gain their suppressive functions.
“This will enhance our ability to generate more effective anti-tumor T cell responses in mice, which then might be translated to human.”
Widespread testing of new therapies for prostate cancer
Posted in Immunotherapy, PROSTATE CANCER, PROSTATE RESEARCH, tagged biological and molecular mechanisms, cancer research, new targeted therapies, prostablog, prostate, prostate blog, PROSTATE CANCER, prostate cancer growth and progression, prostate cancer treatments, prostate treatment, URO TODAY, widespread clinical testing on October 4, 2009| Leave a Comment »
URO TODAY: In the last several years, great strides have been made in our understanding of the biological and molecular mechanisms driving prostate cancer growth and progression, and this has resulted in widespread clinical testing of numerous new targeted therapies. READ MORE>
Leading Kiwi scientist will test his own prostate cancer treatment discovery on himself
Posted in Hormone-refactory, Immunotherapy, PROSTATE CANCER, PROSTATE RESEARCH, PSA tests, Survival, Treatment news, tagged advanced prostate cancer, advanced prostate cancer treatment, cancer research, Dr James Watson, Dr Richard Forster, immune system, immunology, leading NZ scientist, NZ Prostate Cancer Foundation, prostablog, prostate, prostate blog, PROSTATE CANCER, prostate cancer treatments, prostate treatment, prostate treatment debate, prostate-specific antigen, Provenge treatment, PSA, PSA test, University of California on August 3, 2009| Leave a Comment »
PROSTABLOG NZ: A leading NZ scientist has discovered a novel compound he believes will suppress the prostate cancer that is killing him.
Dr James Watson (right) – a former professor at the University of California, now back in NZ – discovered too late he has advanced cancer, so has embarked (with a fellow Kiwi scientist, who also has advanced prostate cancer) on a research project to stop his deadly disease.
He believes he has identified a treatment that will stimulate his immune system to fight the cancer, which has spread beyond his prostate.
He has decided to test the compound on himself, with the assistance of another eminent Auckland medical specialist.
His quest is driven partly by the altruism of finding a viable treatment for all men whose prostate cancer moves to a stage that defies treatment, and partly by his anger at not being diagnosed early when the disease could have been treated easily.
He saw several GPs before one offered him a PSA test, by which time his level was a lethal 987.
He and colleague Dr Richard Forster, an expert on immunology and plant biology, have set up a company to develop their discoveries.
They revealed their progress at the annual conference of the NZ Prostate Cancer Foundation in Napier.
Provenge immunotherapy treatment for advanced prostate cancer emerges well from latest trial, with mild side effects
Posted in Immunotherapy, PROSTATE CANCER, PROSTATE RESEARCH, Provenge, tagged advanced prostate cancer, asthenia (physical weakness), cancer research, cellular immunotherapy, chills, dyspnea (shortness of breath), headache, hormone-refractory, modest toxicity, placebo, prostablog, prostate, prostate blog, PROSTATE CANCER, prostate cancer treatments, prostate treatment, prostate treatment debate, Provenge treatment, PUB MED, pyrexia (fever), Sipuleucel-T, survival benefit, tremor, vomiting, Washington on July 27, 2009| 1 Comment »
JULY 27: PUB MED: A trial involving men with hormone-refractory (advanced) prostate cancer who were treated with Provenge (a cellular immunotherapy product called Sipuleucel-T) had a “survival benefit” and only modest side effects, say the Washington researchers. READ MORE>
The integrated results…demonstrate a survival benefit for patients treated with sipuleucel-T compared with those treated with placebo.
The generally modest toxicity profile, coupled with the survival benefit, suggests a favorable risk-benefit ratio for sipuleucel-T in patients with advanced prostate cancer.
The most common adverse events associated with treatment were chills, pyrexia (fever), headache, asthenia (physical weakness), dyspnea (shortness of breath), vomiting, and tremor.
PROSTATE FUTURE: New drug will be ready for baby boomers
Posted in Immunotherapy, New prostate drugs, PROSTATE CANCER, Prostate drugs, PROSTATE RESEARCH, Treatment news, tagged advanced prostate cancer, Baby Boomers, cancer research, Dendreon, immunotherapy vaccines, prostablog, prostate, prostate blog, PROSTATE CANCER, prostate cancer treatments, prostate treatment, prostate treatment debate, Provenge treatment, U.S. Food and Drug Administration on June 11, 2009| Leave a Comment »
JUNE 11: SEEKING ALPHA.COM: A groundbreaking new treatment for prostate cancer, Provenge, will likely receive US Food and Drug Administration approval and become widely available just as the first Baby Boomers reach 65 in 2010. READ MORE>
